RADIATION
indium-111-exendin SPECT/CT
SPECT/CT imaging after injection with In-111-DTPA-exendin-4
Quantitative GLP-1 Receptor Imaging Correlated to ex Vivo Distribution of In-111-exendin
Status
Terminated
Phase
Not applicable
Enrollment
12
Locations
1
Results
Not posted
Publications
1
Study summary
What the protocol is testing.
The main goal is to study the correlation of pancreatic uptake of In-111-DTPA-exendin-4 (measured by ex vivo counting) with the beta cell mass determined in the pancreatic specimens obtained after surgery.
Full detailed description
In order to fully characterize the highly promising tracer In-111-DTPA-exendin-4 in humans, quantitative SPECT imaging will be correlated to the ex vivo tracer distribution in patients undergoing pancreatectomy or a Whipple procedure. In vivo imaging will be combined with post-pancreatectomy (micro)autoradiography, measurement of In-111-DTPA-exendin-4 concentrations in the pancreas using a gamma counter and morphometric determination of the actual beta cell mass. By this means, the relation between tracer uptake and beta cell mass in non-diabetic patients and T2D patients will be established. These highly relevant data will allow the improvement of the interpretation of clinical quantitative SPECT data in subsequent studies in patients with T1D and T2D. In addition, high uptake has been observed in the duodenum/pyloric area in patients in an ongoing study. At this point in time, it remains unclear which cells are responsible for this uptake. It would be of great interest to identify the GLP-1R positive cells in order to better understand the physiological actions of GLP-1 agonists.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Mar 26, 2019
Study start
Nov 16, 2015
Primary completion
Jun 14, 2021
Study completion
Jun 14, 2021
Results posted
Not reported
Registry updated
Jul 12, 2023
Outcomes
What the study measures.
Primary outcomes
Correlation between the tracer uptake (counts) and beta cell mass (mg)
Time frame · 4 years
The primary objective is the correlation between the ex vivo In-111-exendin tracer accumulation in the pancreas (counts) of patients undergoing pancreatectomy or Whipple procedure, and the beta cell mass (mg) in non- diabetic patients and patients with diabetes.
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Scheduled for partial or complete pancreatectomy or Whipple procedure at Radboudumc Exclusion Criteria: * Resection that provides insufficient amount of tissue * Previous treatment with synthetic Exendin (Exenatide, Byetta®) or Dipeptidyl- Peptidase IV inhibitors * Breast feeding * Pregnancy or the wish to become pregnant within 6 months * Renal disease * Liver disease * Age \< 18 years
Study locations
1 registered sites.
Netherlands. Showing up to 24 locations stored in the fast local snapshot.
Radboud university medical center
Nijmegen, Gelderland, Netherlands
Related trials
More studies on Exenatide.
NCT IDStudyPhase / statusEnrollmentUpdated
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
Ohio State University · Obesity & Overweight · Diabetes (DM)
Not applicable
Recruiting
300
2026-07
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Johns Hopkins University · Multiple Sclerosis
Phase 2
Recruiting
120
2026-07
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
AstraZeneca · Pancreatic Cancer
Not applicable
Recruiting
24,000
2026-06
GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)
Chinese University of Hong Kong · Cerebral Small Vessel Disease
Phase 2
Recruiting
110
2026-06
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy
University Hospital, Bordeaux · Craniopharyngiomas · Hypothalamic Obesity
Phase 3
Completed
42
2026-05
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
Brigham and Women's Hospital · Cardiovascular Events · Type2 Diabetes
Not applicable
Active, not recruiting
781,430
2026-05
Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics
Assistance Publique Hopitaux De Marseille · Obesity · Diabetes
Phase 3
Completed
44
2026-05
Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease
University College, London · Parkinson's Disease
Phase 3
Completed
194
2026-05
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.